Stay updated on Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial
Sign up to get notified when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.

Latest updates to the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page
- CheckyesterdayChange DetectedA site-wide notice announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check8 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2 while the study page remains a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe page now shows a 403 Forbidden error for the study record, with a simple 403 header and navigation replacing the previous content. Many study-related sections and terms were removed, resulting in an error-state page.SummaryDifference18%

- Check57 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6, indicating a small update to the page or its metadata rather than a change to the study details. It does not alter the information presented about the trial.SummaryDifference0.1%

- Check78 days agoChange DetectedFooter now shows Revision: v3.6.5, replacing v3.6.4. This is a minor software version update and does not change study content or page functionality.SummaryDifference0.1%

Stay in the know with updates to Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sustained Release Dalfampridine in Transverse Myelitis Clinical Trial page.